Information Provided By:
Fly News Breaks for November 7, 2019
KURA
Nov 7, 2019 | 08:05 EDT
Wedbush analyst Robert Driscoll reiterated a $30 price target and Outperform rating on Kura Oncology, saying he still views Kura as one of his top picks. Kura is continuing to rationally broaden lead asset tipifarnib's clinical development program ahead of a likely positive outcome for its registration-directed study in HRAS-mutant head and neck squamous cell carcinoma in 2020, Driscoll tells investors in a research note.
News For KURA From the Last 2 Days
There are no results for your query KURA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.